These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36030519)

  • 1. Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study.
    Onuoha E; Smith AD; Cannon R; Khushman M; Kim H
    J Gastrointest Cancer; 2023 Sep; 54(3):776-781. PubMed ID: 36030519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Radiologic Predictors of Response to Atezolizumab-Bevacizumab in Advanced Hepatocellular Carcinoma.
    Choi SJ; Chung SW; Choi J; Kim KM; Kim HD; Yoo C; Ryoo BY; Lee SS; Choi WM; Choi SH
    Cancer Res Treat; 2024 Oct; 56(4):1219-1230. PubMed ID: 38726509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.
    Gao X; Zhao R; Ma H; Zuo S
    BMC Cancer; 2023 Jul; 23(1):635. PubMed ID: 37415136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.
    Kuzuya T; Kawabe N; Hashimoto S; Miyahara R; Sawaki A; Nakano T; Nakaoka K; Tanaka H; Miyachi Y; Mii A; Kamejima S; Takahara T; Kato Y; Sugioka A; Hirooka Y
    Oncology; 2022; 100(1):12-21. PubMed ID: 34731863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Ippolito D; Querques G; Pecorelli A; Talei Franzesi C; Okolicsanyi S; Strazzabosco M; Sironi S
    J Comput Assist Tomogr; 2019; 43(2):206-213. PubMed ID: 30407241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
    Limousin W; Laurent-Puig P; Ziol M; Ganne-Carrié N; Nahon P; Ait-Omar A; Seror O; Sidali S; Campani C; Blanc P; Lermine A; Marisa L; Zucman-Rossi J; Nault JC
    J Hepatol; 2023 Dec; 79(6):1450-1458. PubMed ID: 37647991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organ-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study.
    Cheon J; Jung S; Kim JS; Kang B; Kim H; Chan LL; Becker L; Gaillard VE; Chan SL; Kim C; Chon HJ
    Liver Int; 2024 Aug; 44(8):1961-1970. PubMed ID: 38618972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
    Takada H; Yamashita K; Osawa L; Komiyama Y; Nakakuki N; Muraoka M; Suzuki Y; Sato M; Kobayashi S; Yoshida T; Takano S; Maekawa S; Enomoto N
    Oncology; 2023; 101(10):655-663. PubMed ID: 37379802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment.
    Takakusagi S; Tanaka H; Naganuma A; Kakizaki S; Shibuya K; Ohno T; Takagi H; Uraoka T
    Clin J Gastroenterol; 2023 Jun; 16(3):407-415. PubMed ID: 36750524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma.
    Kim HD; Park YG; Kim S; Kim KP; Park SR; Ryu MH; Ryoo BY; Yoo C
    Hepatol Int; 2024 Jun; 18(3):973-983. PubMed ID: 38214792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
    Hayakawa Y; Tsuchiya K; Kurosaki M; Yasui Y; Kaneko S; Tanaka Y; Ishido S; Inada K; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Izumi N
    Invest New Drugs; 2022 Apr; 40(2):392-402. PubMed ID: 34586531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
    Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
    Takeuchi Y; Nouso K; Fujioka SI; Kariyama K; Kobashi H; Uematsu S; Moriya A; Hagihara H; Takabatake H; Nakamura S; Yabushita K; Kikuchi T; Oyama A; Adachi T; Wada N; Onishi H; Shiraha H; Takaki A
    Cancer Med; 2023 Sep; 12(17):17559-17568. PubMed ID: 37537956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
    Hosoda S; Suda G; Sho T; Ogawa K; Kimura M; Yang Z; Yoshida S; Kubo A; Tokuchi Y; Kitagataya T; Maehara O; Ohnishi S; Nakamura A; Yamada R; Ohara M; Kawagishi N; Natsuizaka M; Nakai M; Morikawa K; Furuya K; Baba M; Yamamoto Y; Suzuki K; Izumi T; Meguro T; Terashita K; Ito J; Miyagishima T; Sakamoto N
    Liver Cancer; 2023 Jun; 12(2):156-170. PubMed ID: 37325489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma.
    Villalobos A; Dabbous HH; Little O; Gbolahan OB; Akce M; Lilly MA; Bercu Z; Kokabi N
    Curr Oncol; 2023 Nov; 30(12):10100-10110. PubMed ID: 38132368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
    Kaufmann S; Thaiss WM; Schulze M; Bitzer M; Lauer U; Nikolaou K; Horger M
    Acta Radiol; 2018 Jul; 59(7):765-772. PubMed ID: 28927298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
    Zeng Q; Klein C; Caruso S; Maille P; Allende DS; Mínguez B; Iavarone M; Ningarhari M; Casadei-Gardini A; Pedica F; Rimini M; Perbellini R; Boulagnon-Rombi C; Heurgué A; Maggioni M; Rela M; Vij M; Baulande S; Legoix P; Lameiras S; ; Bruges L; Gnemmi V; Nault JC; Campani C; Rhee H; Park YN; Iñarrairaegui M; Garcia-Porrero G; Argemi J; Sangro B; D'Alessio A; Scheiner B; Pinato DJ; Pinter M; Paradis V; Beaufrère A; Peter S; Rimassa L; Di Tommaso L; Vogel A; Michalak S; Boursier J; Loménie N; Ziol M; Calderaro J
    Lancet Oncol; 2023 Dec; 24(12):1411-1422. PubMed ID: 37951222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.